FDA gives accelerated approval to Genmab and Seagen's cervical cancer drug

Genmab and Seagen have received accelerated approval from the FDA for tisotumab vedotin, used to treat recurring or metastatic cervical cancer.

Photo: Joost Melis / Genmab / PR

Genmab and its partner Seagen have obtained accelerated approval for tisotumab vedotin, commercial name Tivdak, for the treatment of recurring or metastatic cervical cancer, from the US Food and Drug Administration (FDA).

"Tivdak's approval as a monotherapy in the US is an important milestone for women with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, as they are in need of a new treatment option and we look forward to making it available to them," says Jan van de Winkel, CEO at Genmab, in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs